Reduction in IP3R levels and blocking of RyR activity was shown to alleviate AD symptoms in AD mouse models solidifying IP3R and RyR-mediated Ca2+ release from the ER in neurons as therapeutic targets for AD [129,130]. This evidence concerns the gene RYR2 and Alzheimer disease.